Androgen deprivation therapy: A survival benefit or detriment in men with high-risk prostate cancer?

ONCOLOGY

Volumn 24, Issue 9, 2010, Pages

  Fang, L Christine ^a   Merrick, Gregory S ^b,c   Wallner, Kent E ^d,e  

^a UNIVERSITY OF TEXAS   (United States)

^b WHEELING HOSPITAL   (United States)

^c WHEELING JESUIT UNIVERSITY   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

^e CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GONADORELIN AGONIST;

ADJUVANT CHEMOTHERAPY; ANDROGEN DEPRIVATION THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG MECHANISM; HIGH RISK PATIENT; HUMAN; PROSTATE CANCER; RADIATION DOSE; REVIEW;

EID: 77958057109     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997. (Pubitemid 27318990)
2. Smith MR: Androgen deprivation therapy for prostate cancer: New concepts and concerns. Curr Opin Endocrinol Diabetes Obes 14:247-254, 2007. (Pubitemid 46684481)
3. Shahinian VB, Kuo YF, Freeman JL, et al: Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer. J Clin Oncol 25:5359-5365, 2007. (Pubitemid 350232210)
4. Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22:232-240, 1972.
5. Seidenfeld J, Samson DJ, Hasselblad V, et al: Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. Ann Intern Med 132:566-577, 2000.
6. Kyprianou N, English HF, Isaacs JT: Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50:3748-3753, 1990. (Pubitemid 20194126)
7. Joon DL, Hasegawa M, Sikes CI, et al: Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 38:1071-1077, 1997. (Pubitemid 27353688)
8. Nakashima J, Imai Y, Tachibana M, et al: Effects of endocrine therapy on the primary lesion in patients with prostate carcinoma as evaluated by endorectal magnetic resonance imaging. Cancer 80:237-241, 1997.
9. Mercader M, Bodner BK, Moser MT, et al: T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A 98:14565-14570, 2001.
10. Cooperberg MR, Grossfeld GD, Lubeck DP, et al: National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95:981-989, 2003.
11. Shahinian VB, Kuo YF, Freeman JL, et al: Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103:1615-1624, 2005. (Pubitemid 40490022)
12. Weight CJ, Klein EA, Jones JS: Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer 112:2195-2201, 2008.
13. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360:103-106, 2002.
14. Pilepich MV, Winter K, Lawton CA, et al: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61:1285-1290, 2005. (Pubitemid 40470408)
15. Roach M, 3rd, Bae K, Speight J, et al: Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 26:585-591, 2008. (Pubitemid 351264352)
16. DAmico AV, Chen MH, Renshaw AA, et al: Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA 299:289-295, 2008.
17. Dearnaley DP, Sydes MR, Graham JD, et al: Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 8:475-487, 2007.
18. Kuban DA, Tucker SL, Dong L, et al: Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67-74, 2008.
19. Peeters ST, Heemsbergen WD, Koper PC, et al: Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990-1996, 2006.
20. Zietman AL, DeSilvio ML, Slater JD, et al: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294:1233-1239, 2005. (Pubitemid 41352111)
21. Nguyen KH, Horwitz EM, Hanlon AL, et al: Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer? Int J Radiat Oncol Biol Phys 57:377-383, 2003.
22. DAmico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998. (Pubitemid 28445094)
23. Dattoli M, Wallner K, True L, et al: Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 110:551-555, 2007. (Pubitemid 47106143)
24. Merrick GS, Butler WM, Wallner KE, et al: Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. Int J Radiat Oncol Biol Phys 68:34-40, 2007.
25. Stock RG, Ho A, Cesaretti JA, et al: Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys 66:389-394, 2006. (Pubitemid 44332760)
26. Lee LN, Stock RG, Stone NN: Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 52:444-452, 2002.
27. Stone NN, Potters L, Davis BJ, et al: Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason Score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 73:341-346, 2009.
28. Aus G, Abrahamsson PA, Ahlgren G, et al: Three-month neoadjuvant hormonal therapy before radical prostatectomy: A 7-year follow-up of a randomized controlled trial. BJU Int 90:561-566, 2002.
29. Meyer F, Moore L, Bairati I, et al: Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure. J Urol 162:2024-2028, 1999.
30. Soloway MS, Pareek K, Sharifi R, et al: Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167:112-116, 2002.
31. Schulman CC, Debruyne FM, Forster G, et al: 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 38:706-713, 2000.
32. Messing EM, Manola J, Yao J, et al Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472-479, 2006.
33. Horwitz EM, Bae K, Hanks GE, et al: Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26:2497-2504, 2008.
34. Bolla M, de Reijke TM, Van Tienhoven G, et al: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516-2527, 2009.
35. Lawton CA, DeSilvio M, Roach M, 3rd, et al: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69:646-655, 2007. (Pubitemid 47418390)
36. Basaria S, Lieb J, 2nd, Tang AM, et al: Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 56:779-786, 2002.
37. Lee H, McGovern K, Finkelstein JS, et al: Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 104:1633-1637, 2005.
38. Berruti A, Dogliotti L, Terrone C, et al: Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167:2361-2367; discussion 2367, 2002.
39. Smith MR, Finkelstein JS, McGovern FJ, et al: Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599-603, 2002. (Pubitemid 34158224)
40. Marin P, Holmang S, Jonsson L, et al: The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 16:991-997, 1992. (Pubitemid 23010023)
41. Braga-Basaria M, Dobs AS, Muller DC, et al: Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24:3979-3983, 2006. (Pubitemid 46630747)
42. Basaria S, Muller DC, Carducci MA, et al: Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106:581-588, 2006.
43. Nishiyama T, Ishizaki F, Anraku T, et al: The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 90:657-660, 2005.
44. Dockery F, Bulpitt CJ, Agarwal S, et al: Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 104:195-201, 2003. (Pubitemid 36238052)
45. Smith MR, Lee H, Nathan DM: Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91:1305-1308, 2006.
46. Isomaa B, Almgren P, Tuomi T, et al: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001. (Pubitemid 32893993)
47. Keating NL, OMalley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448-4456, 2006.
48. Alibhai SM, Duong-Hua M, Sutradhar R, et al: Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 27:3452-3458, 2009.
49. DAmico AV, Denham JW, Crook J, et al: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25:2420-2425, 2007.
50. Tsai HK, DAmico AV, Sadetsky N, et al: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516-1524, 2007. (Pubitemid 351767235)
51. Pickles T, Agranovich A, Berthelet E, et al: Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 94:362-367, 2002. (Pubitemid 34081364)
52. Efstathiou JA, Bae K, Shipley WU, et al: Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 27:92-99, 2009.
53. Efstathiou JA, Bae K, Shipley WU, et al: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92-02. Eur Urol 54:816-823, 2008.
54. Daniell HW, Dunn SR, Ferguson DW, et al: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163:181-186, 2000.
55. Diamond T, Campbell J, Bryant C, et al: The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: Longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83:1561-1566, 1998.
56. Maillefert JF, Sibilia J, Michel F, et al: Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161:1219-1222, 1999.
57. Shahinian VB, Kuo YF, Freeman JL, et al: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154-164, 2005.
58. Smith MR, Boyce SP, Moyneur E, et al: Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 175:136-139; discussion 139, 2006.
59. Oefelein MG, Ricchiuti V, Conrad W, et al: Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168:1005-1007, 2002.
60. Beyer DC, McKeough T, Thomas T: Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61:1299-1305, 2005.
61. Nanda A, Chen MH, Braccioforte MH, et al: Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302:866-873, 2009.
62. Bria E, Cuppone F, Giannarelli D, et al: Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Meta-analysis of randomized trials. Cancer 115:3446-3456, 2009.
63. Denham JW, Steigler A, Lamb DS, et al: Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6:841-850, 2005.
64. Zwergel U, Suttman H, Schroeder T: Outcome of prostate cancer patients with initial PSA > or = 20 ng/ml undergoing radical prostatectomy. Eur Urol 52:1058-1065, 2007.